We are upgrading the repository! A content freeze is in effect until December 6th, 2024 - no new submissions will be accepted; however, all content already published will remain publicly available. Please reach out to repository@u.library.arizona.edu with your questions, or if you are a UA affiliate who needs to make content available soon. Note that any new user accounts created after September 22, 2024 will need to be recreated by the user in November after our migration is completed.
Impaired cardiac and peripheral hemodynamic responses to inhaled β₂-agonist in cystic fibrosis
Affiliation
School of Kinesiology, University of MinnesotaCollege of Pharmacy, University of Arizona
Department of Anesthesiology, Mayo Clinic
Department of Cardiovascular Diseases, Mayo Clinic
Department of Pediatrics, University of Arizona
Issue Date
2015
Metadata
Show full item recordPublisher
BioMed CentralCitation
Van Iterson et al. Respiratory Research (2015) 16:103 DOI 10.1186/s12931-015-0270-yJournal
Respiratory ResearchRights
© 2015 Van Iterson et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).Collection Information
This item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.Abstract
BACKGROUND: Pulmonary system dysfunction is a hallmark of cystic fibrosis (CF) disease. In addition to impaired cystic fibrosis transmembrane conductance regulator protein, dysfunctional β2-adrenergic receptors (β2AR) contribute to low airway function in CF. Recent observations suggest CF may also be associated with impaired cardiac function that is demonstrated by attenuated cardiac output (Q), stroke volume (SV), and cardiac power (CP) at both rest and during exercise. However, β2AR regulation of cardiac and peripheral vascular tissue, in-vivo, is unknown in CF. We have previously demonstrated that the administration of an inhaled β-agonist increases SV and Q while also decreasing SVR in healthy individuals. Therefore, we aimed to assess cardiac and peripheral hemodynamic responses to the selective β2AR agonist albuterol in individuals with CF. METHODS: 18 CF and 30 control (CTL) subjects participated (ages 22 ± 2 versus 27 ± 2 and BSA = 1.7 ± 0.1 versus 1.8 ± 0.0 m2, both p < 0.05). We assessed the following at baseline and at 30- and 60-minutes following nebulized albuterol (2.5mg diluted in 3.0mL of normal saline) inhalation: 12-lead ECG for HR, manual sphygmomanometry for systolic and diastolic blood pressure (SBP and DBP, respectively), acetylene rebreathe for Q and SV. We calculated MAP = DBP + 1/3(SBP-DBP); systemic vascular resistance (SVR) = (MAP/Q)•80; CP = Q•MAP; stroke work (SW) = SV•MAP; reserve (%change baseline to 30- or 60-minutes). Hemodynamics were indexed to BSA (QI, SVI, SWI, CPI, SVRI). RESULTS: At baseline, CF demonstrated lower SV, SVI, SW, and SWI but higher HR than CTL (p < 0.05); other measures did not differ. At 30-minutes, CF demonstrated higher HR and SVRI, but lower Q, SV, SVI, CP, CPI, SW, and SWI versus CTL (p < 0.05). At 60-minutes, CF demonstrated higher HR, SVR, and SVRI, whereas all cardiac hemodynamics were lower than CTL (p < 0.05). Reserves of CP, SW, and SVR were lower in CF versus CTL at both 30 and 60-minutes (p < 0.05). CONCLUSIONS: Cardiac and peripheral hemodynamic responsiveness to acute β2AR stimulation via albuterol is attenuated in individuals with CF, suggesting β2AR located in cardiac and peripheral vascular tissue may be dysfunctional in this population.EISSN
1465-993XPubMed ID
26341519PubMed Central ID
PMC4560914Version
Final published versionAdditional Links
http://www.respiratory-research.com/content/16/1/103ae974a485f413a2113503eed53cd6c53
10.1186/s12931-015-0270-y [doi]
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2015 Van Iterson et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
Related articles
- Cystic Fibrosis Transmembrane Conductance Regulator Genotype, Not Circulating Catecholamines, Influences Cardiovascular Function in Patients with Cystic Fibrosis.
- Authors: Bisch AL, Wheatley CM, Baker SE, Peitzman ER, Van Iterson EH, Laguna TA, Morgan WJ, Snyder EM
- Issue date: 2019
- Effects of an inhaled β2-agonist on cardiovascular function and sympathetic activity in healthy subjects.
- Authors: Snyder EM, Wong EC, Foxx-Lupo WT, Wheatley CM, Cassuto NA, Patanwala AE
- Issue date: 2011 Aug
- Influence of genetic variation of the β2-adrenergic receptor on lung diffusion in patients with cystic fibrosis.
- Authors: Traylor BR, Wheatley CM, Skrentny TT Jr, Foxx-Lupo WT, Phan H, Patanwala AE, Morgan WJ, Daines CL, Sprissler R, Snyder EM
- Issue date: 2011 Oct
- Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis.
- Authors: Wheatley CM, Baker SE, Morgan MA, Martinez MG, Liu B, Rowe SM, Morgan WJ, Wong EC, Karpen SR, Snyder EM
- Issue date: 2015 Aug
- The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction.
- Authors: Reddy YNV, Obokata M, Koepp KE, Egbe AC, Wiley B, Borlaug BA
- Issue date: 2019 Jan 18